Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with or without pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin in platinum-resistant or platinum-refractory ovarian cancer
NL-OMON47622Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Avelumab alone, Avelumab plus pegylated liposomal doxorubicin and Pegylated liposomal doxorubicin alone (3 arms). Primary endpoints: Overall survival and Progression-free survival by blinded independent central review. Started Dec 2016; status: active, not recruiting.
02
Drugs
avelumabdoxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON47622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47622.